Background and Aims: Extraintestinal manifestations [EIMs] such as arthritis/arthralgia are common in inflammatory bowel disease. We performed post hoc analyses of data from the GEMINI studies to evaluate the effect of vedolizumab, a gut-selective anti-trafficking agent, on arthritis/arthralgia. Methods: Sustained resolution of baseline arthritis/arthralgia, worsening of baseline arthritis/ arthralgia, the occurrence of new arthritis/arthralgia, and the composite of new/worsening arthritis/ arthralgia were evaluated. Cox modelling was used for time-to-event analysis. The influence of corticosteroid-tapering was also investigated. Results: In Crohn's disease [CD] patients, vedolizumab was significantly less likely than placebo to be associated with new/worsening arthritis/arthralgia (hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.44-0.89). Similar incidences of sustained resolution of arthritis/arthralgia occurred with vedolizumab and placebo. In CD patients on corticosteroids at baseline, a decrease in corticosteroid dose increased the risk of new/worsening arthritis/arthralgia (odds ratio [OR], 7.49; 95% CI, 3.50-15.97) regardless of treatment; and in those achieving corticosteroid-free status, arthritis/arthralgia was less likely with vedolizumab than with placebo [HR, 0.14; 95% CI, 0.05-0.35]. In ulcerative colitis [UC] patients, vedolizumab and placebo showed a similar incidence of new/worsening of arthritis/arthralgia. In UC patients on corticosteroid at baseline, arthritis/ arthralgia was more likely in those achieving corticosteroid-free status than in those continuing corticosteroids .11]); and in those achieving corticosteroid-free status, the incidence of arthritis/arthralgia was similar with vedolizumab and placebo. Conclusions: Vedolizumab therapy was associated with a reduced likelihood of new/worsening arthritis/arthralgia in CD and no increased incidence of these events in UC. 
Introduction
Extraintestinal manifestations [EIMs] of inflammatory bowel disease [IBD] occur in up to 55% of patients with Crohn's disease [CD] and 35% of those with ulcerative colitis [UC] . [1] [2] [3] Although arthritis/arthralgia is the most common EIM in both disorders, 2, 3 multiple organs may be affected including skin, eye and liver. While the pathophysiology of EIMs is poorly understood, current theories indicate an immune response to antigens entering the systemic circulation from an inflamed gastrointestinal mucosa or migration of pro-inflammatory leucocytes from the gut to target organs. 4, 5 Effective management of EIMs is an important component of patient care. Given that corticosteroids and tumour necrosis factor [TNF] antagonists act systemically, treatment with these agents usually controls arthritis/arthralgia and other EIMs. [6] [7] [8] However, TNF antagonists are not uniformly effective for either bowel-related symptoms or EIMs. Approximately one-third of patients fail to respond to induction therapy with these agents, and relapse in responders is common. 9 Furthermore, TNF antagonists are associated with an increased risk of serious infection, drug-induced arthralgias and psoriasiform skin lesions. [10] [11] [12] Consequently, a need exists for treatments that provide sustained clinical remission, are safe and well-tolerated, and control EIMs.
Vedolizumab [Entyvio ® , Takeda Pharmaceuticals America, Inc., Deerfield, IL, USA], a monoclonal antibody targeting the α 4 β 7 integrin that selectively blocks lymphocyte trafficking to the gastrointestinal tract, is approved for the treatment of patients with moderately to severely active IBD. [13] [14] [15] Vedolizumab has demonstrated long-term effectiveness [16] [17] [18] [19] [20] and has a favourable safety profile with a low risk of serious infections. 21 However, it is currently unknown whether a gut-selective mechanism of action is optimal for controlling EIMs. On the one hand, if the pathophysiology of these conditions is driven by mucosal inflammation, treatment directed to that process should be effective. Alternatively, if EIMs are the result of systemic immune activation, then a gut-selective therapy might be less effective than corticosteroids or TNF antagonists. To investigate this question, we evaluated the effect of vedolizumab treatment on new and existing EIMs using data from the pivotal GEMINI clinical trials. 16,17 GEMINI 3 [CD] was a phase 3, randomized, placebo-controlled 10-week induction study predominantly in patients refractory to TNF antagonists. 18 For all three studies, the protocols were approved by an investigational review board at each centre, and all patients gave written informed consent. [16] [17] [18] The current analyses investigated three treatment groups from GEMINI 1 and 2 [ Supplementary Figure 1] . The PLA group comprised patients receiving placebo during induction and maintenance phases. The VDZ/PLA group comprised vedolizumab responders at Week 6 after two induction doses at Weeks 0 and 2, who were subsequently randomized to placebo during maintenance. The VDZ group comprised patients receiving vedolizumab during induction and maintenance, and included both vedolizumab responders [both Q4W and Q8W dosing regimens during maintenance] and non-responders [Q4W during maintenance] at Week 6. GEMINI 3 included VDZ and PLA groups only; patients received three induction doses at Weeks 0, 2 and 6.
Methods

Study populations and treatment groups
EIM data and endpoints
The EIMs evaluated were arthritis/arthralgia, aphthous stomatitis, erythema nodosum, iritis/uveitis and pyoderma gangrenosum.
In GEMINI 2 and 3, EIM source data included the Crohn's Disease Activity Index [CDAI] and reported adverse events [AEs] . Baseline prevalence and distribution of these outcomes were documented using the CDAI diary card, which captured the presence of each EIM [yes/no] at screening, baseline and every 4 weeks during treatment until the end of the study. AE report forms captured events that were new/worsening in severity during treatment.
The following endpoints were defined for GEMINI 2 and 3: [1] sustained resolution of a baseline EIM [defined as a report of a baseline EIM and two or more subsequent study visits with no EIM reports, without recurrence until study completion; captured using the CDAI]; [2] occurrence of a new EIM [no report at baseline using CDAI, and captured using CDAI or AE report forms at any subsequent study visit]; [3] worsening of a baseline EIM [reported at baseline using CDAI, and reported as an AE at any follow-up visit]; and [4] composite of occurrence of a new EIM or worsening of a baseline EIM [capturing the overall worsening aspect of EIMs; subsequently referred to as 'new/worsening EIM'].
In GEMINI 1, only AE report forms were available for analysis and it was not possible to distinguish between new or worsening of baseline EIMs. Therefore, only the composite endpoint of a new/ worsening EIM was captured. Unlike the CDAI, the Mayo score, which is used to assess clinical disease activity in UC, does not include EIMs as a measure of disease activity.
Statistical methods
Endpoints were evaluated in the overall safety population and in the subgroup of patients receiving concomitant corticosteroids at baseline. Kaplan-Meier plots and Cox regression models were generated to describe the time-to-event course for the designated endpoints. Results were based upon actuarial risk estimates, and expressed as hazard ratios [HRs] with 95% confidence intervals [CIs] with adjustment for covariation using the Cox model. Supplementary Table 1 lists all covariates tested and the significant covariates included in each Cox model.
In the corticosteroid subgroup, the endpoint of occurrence of new/worsening arthritis was analysed for those who achieved or did not achieve corticosteroid-free status. In addition, the effect of a decrease in corticosteroid dose in the 4 weeks prior to this endpoint was assessed using a generalized estimating equations model for repeated measures with treatment group, prior exposure to TNF antagonist, baseline corticosteroid dose and time-dependent corticosteroid dose decrease as explanatory covariates.
The potential associations between sustained resolution of baseline arthritis/arthralgia or new/worsening arthritis/arthralgia and clinical remission or response [CDAI score ≤150 or ≥150-point decrease in CDAI score, respectively] were explored using a chisquare test at weeks 6 and 52 in GEMINI 1 and 2, and at weeks 6 and 10 in GEMINI 3.
Results
Baseline characteristics
Baseline characteristics of CD and UC patients with baseline EIMs included in these analyses were generally similar between treatment groups in all three GEMINI studies [ Table 1 ]. Over half of the patients in each study received concomitant corticosteroids, while approximately 50% had failed prior TNF antagonist therapy in GEMINI 1 and 2, compared with 76% of those in GEMINI 3. Given the high rate of arthritis/arthralgia and the low occurrence of other EIMs, the analysis of endpoints focused exclusively on arthritis/arthralgia.
Crohn's disease: GEMINI 2 and 3
In GEMINI 2, a total of 554 EIM events were recorded at any time between baseline and the end of treatment. 
Sustained resolution of baseline arthritis/arthralgia
In the CD patients in these trials, the prevalence and distribution of EIMs at baseline were similar for all treatment groups [ Table 2 ].
The Kaplan-Meier plots of time to sustained resolution of arthritis/arthralgia in GEMINI 2 are shown in Figure 1A . Although the results of the Cox analysis favoured patients assigned to vedolizumab over placebo, the differences were not statistically significant In GEMINI 2, lower rates of early withdrawal for any cause were reported in CD patients with sustained resolution of arthritis/ arthralgia compared to those without sustained resolution across all treatment groups [36.1% vs 72.0% for the overall population].
New and new/worsening arthritis/arthralgia
The incidence of all new EIMs, except for arthritis/arthralgia, in GEMINI 2 was low and not substantially different between treatment groups [ Table 3 and Figure 1B In GEMINI 3, the incidence of new EIMs was low and similar between treatment groups, with new arthritis/arthralgia as the most common EIM [ Table 3 ]. The Kaplan-Meier plot of time to new arthritis/arthralgia showed low and similar event probability in both treatment groups [ Figure 1C ]. Cox analysis found no difference in the likelihood of new arthritis/arthralgia in the VDZ than the PLA group [HR, 0.75; 95% CI, 0.37-1.53] [Supplementary Figure 3B] .
In GEMINI 2, survival analysis showed a significant difference in new/worsening arthritis/arthralgia between treatment groups. The Kaplan-Meier plot of time to new/worsening arthritis/arthralgia is shown in Figure 1D There were no notable differences in any-cause withdrawal before study end between CD patients with or without new/worsening arthritis/arthralgia in GEMINI 2 [59.4% vs 62.7%] or GEMINI 3 [5.7% vs 12.9%].
Influence of corticosteroid therapy
In GEMINI 2, in the 50% [n = 278/553] of patients with baseline EIM on concomitant corticosteroids, Cox time-dependent analysis indicated that the VDZ group was significantly more likely to achieve sustained resolution of baseline arthritis/arthralgia com- Importantly, an increase in the incidence of arthritis/arthralgia in the 4 weeks after corticosteroid dose-decrease was observed in patients receiving corticosteroids at baseline in GEMINI 2 [Supplementary Figure 5] . Repeated-measures analysis showed an increased rate of new/worsening arthritis/arthralgia events when the corticosteroid dose was decreased (odds ratio Table 4 ]. Kaplan-Meier plots of time to arthritis/ arthralgia showed low and similar event probabilities in all treatment groups [ Figure 1E ]. Cox analysis showed that there was no significant difference in the relative likelihood of events [VDZ vs PLA: HR, 0.99; 95% CI, 0.52-1.90; and VDZ/PLA vs PLA: HR, 1.52; 95% CI, 0.70-3.28] [Supplementary Figure 6] .
In GEMINI 1, the rates of any-cause withdrawals before study end were generally similar in patients with, versus those without, new/worsening arthritis/arthralgia across treatment groups [51.8% vs 58.9% in the overall population]. 
Potential association between clinical response/ remission status and arthritis/arthralgia
In CD patients in GEMINI 2, both clinical response and clinical remission at weeks 6 and 52 were significantly associated with better sustained resolution of baseline arthritis/arthralgia [p < 0.05]. In all three GEMINI studies in both CD and UC patients, no association was observed between clinical response/remission status and new/ worsening EIMs.
Discussion
These analyses of GEMINI 2 and 3 trial data show that the rate of sustained resolution of baseline arthritis/arthralgia was nominally . In GEMINI 1 and 2, the VDZ group includes both induction responders and non-responders, the VDZ/PLA group is responders only, and the PLA group is both responders and non-responders. CD, Crohn's disease; PLA, placebo; VDZ, vedolizumab; UC, ulcerative colitis.
higher in patients with CD receiving vedolizumab than those assigned to placebo. Furthermore, patients who received vedolizumab during the maintenance phase of GEMINI 2 were 45% less likely to develop new arthritis/arthralgia than patients who received placebo [HR, 0.55; 95% CI, 0.36-0.84] and 37% less likely to develop either new/worsening arthritis/arthralgia [HR, 0.63; 95% CI, 0.44-0.89]. In GEMINI 2, clinical response and remission at weeks 6 and 52 were associated with sustained resolution of arthritis/arthralgia. These effects were not evident in GEMINI 3; this was a short-term induction study and the lower number of events observed may have precluded identification of this treatment benefit.
In GEMINI 1, patients with UC developed new/worsening arthritis/arthralgia with a similar incidence across the treatment groups. It could be speculated that differences in underlying pathophysiology between CD and UC might account for these disparate results; however, another important explanation lies in the methods used for EIM data collection in the clinical trials. Both baseline and monthly CDAI records plus continuous AE reports throughout the study were used for CD, while AE reports alone were used for data collection for UC.
Collectively, these data indicate that treatment with vedolizumab for up to 52 weeks is not associated with new/worsening arthritis/ arthralgia compared with placebo in CD or UC patients. Moreover, vedolizumab treatment was associated with a lower risk of new or worsening of baseline arthritis/arthralgia in CD patients. Prior TNF antagonist exposure in both UC and CD patients was associated with a greater likelihood of experiencing new/worsening arthritis/ arthralgia compared with TNF antagonist-naive status, independent of whether patients were randomized to vedolizumab or placebo. The explanation for this finding is not obvious; however, these patients had longer disease durations and, consistent with other studies, were less likely to respond to treatment, thereby suggesting more severe underlying disease.
EIMs as an adverse event associated with vedolizumab treatment have been reported in the pivotal GEMINI studies. 13, 14 Pooled clinical data showed a higher incidence of arthralgia with vedolizumab than with placebo [11.6% vs 9.8%] but lower incidence of other objective joint-related events, such as arthropathies, joint effusions and joint swelling [3.1% vs 5.4%]; few of these events led to discontinuation. 22 In post-marketing safety studies, joint-related events, including mostly arthralgia, were infrequent non-serious events [526 events during 46 798 patient-years of vedolizumab exposure; 75% did not discontinue treatment]. 22 Moreover, published reports have described 'paradoxical worsening' of arthralgias following treatment with vedolizumab. 23, 24 However, we believe that the existing literature regarding the efficacy of vedolizumab in controlling EIMs is biased due to the usual limitations of observational studies-a lack of controls and an absence of blinding, 23 coupled with the notion that mucosal targeted therapy cannot control non-intestinal manifestations of systemic diseases. The latter hypothesis is not supported by our data. Furthermore, one of the striking findings of our study was the strength of the association between corticosteroid withdrawal and worsening of EIMs, a factor that to our knowledge was not considered in any of the previous studies reporting a putative association between treatment with vedolizumab and worsening of EIMs. 22, 23 In this respect, our results revealed two interesting insights into the use of concomitant corticosteroid therapy in these patients. First, CD patients receiving concomitant corticosteroids at baseline had a more than two-fold, significantly greater likelihood of sustained resolution of arthritis/arthralgia and fewer new/worsening events when receiving vedolizumab compared with placebo. This contrasts with results in the overall population, which favoured vedolizumab over placebo, but were not significantly different. Although this subgroup analysis should be interpreted cautiously, it suggests a potential beneficial interaction for combined vedolizumab and corticosteroid therapy in controlling EIMs. This observation is potentially relevant to clinical practice. However, it is important to note that a similar relationship was not observed in UC patients. Second, to our knowledge this study is the first to quantitatively evaluate the association between withdrawal of corticosteroids and arthritic symptoms. Although the development of arthralgia following withdrawal of corticosteroid therapy is generally accepted by clinicians, this phenomenon has not been well studied. 6 In the current analysis, a reduction in corticosteroid dose in CD patients using concomitant corticosteroids at baseline was associated with a seven-fold increased risk of new/worsening arthritis/arthralgia within a 4-week time frame, regardless of whether patients were receiving vedolizumab or placebo. This observation underlines that short-term worsening or new onset of arthritis/arthralgia following corticosteroid tapering is a common occurrence and should not necessarily be causally attributed to corticosteroid-sparing agents such as vedolizumab, [20] [21] [22] TNF antagonists 25 or ustekinumab. 26 It could be speculated that the co-administration of a systemically active anti-inflammatory therapy, such as a TNF antagonist, in this context might mask clinical symptoms of arthralgia related to corticosteroid withdrawal.
The finding that vedolizumab treatment reduced the likelihood of new and new/worsening arthritis/arthralgia has potential implications regarding the pathophysiology of EIMs in IBD. Some EIMs, such as peripheral arthritis, have been associated with bowel inflammation; others, such as pyoderma gangrenosum or ankylosing spondylitis, are proposed to occur independent of intestinal inflammation. 27 Our observations are consistent with the theory that control of inflammation in the gut compartment alone is effective in reducing systemic inflammation and support development of orally administered antibodies or peptides targeting cytokines or adhesion molecules within the gut compartment with the intent of minimizing systemic immunosuppression. 28 Previous real-world studies have shown that vedolizumab can reduce inflammatory EIMs that occur in parallel with intestinal inflammation while also showing that paradoxical inflammation may arise in some patients, 23, 24 similar to what has been reported previously in clinical studies of TNF antagonists. 11, 12 Our study had several limitations. First, validated instruments to evaluate IBD-related EIMs were not available. We used CDAI diary cards and clinical standardized reporting of AEs to assess these events, which is a relatively insensitive approach, rather than more specific measures of EIMs, which were not part of the GEMINI protocols. Accordingly, the study was not specifically designed or powered to evaluate EIMs. Thus, EIMs were under-reported in both CD and UC patient populations, and the low frequency of most EIMs except arthritis/arthralgia precluded analysis of skin, eye and liver disorders. This under-reporting was less likely in CD patients who, unlike UC patients, were asked directly about EIM occurrence as part of the CDAI assessment. The incidence of EIMs in the GEMINI 2 CD population was approximately three-fold that observed in the GEMINI 1 UC population. Notwithstanding the difference in reporting, we believe that these results are consistent with the literature, which shows the reported incidence of EIMs is higher in CD than in UC. [1] [2] [3] Second, it was necessary to deconstruct the original randomized designs of GEMINI 1 and 2 to assess patient cohorts receiving continuous vedolizumab, vedolizumab induction followed by placebo maintenance [VDZ/PLA group], and those receiving continuous placebo. Lack of true randomization makes the findings susceptible to bias. However, despite these limitations, this study evaluated a large number of patients in whom outcomes were collected using standardized methods with both patients and investigators unaware of treatment assignment.
In conclusion, analyses of the GEMINI studies indicate that long-term treatment with vedolizumab is not associated with new occurrences or worsening of arthritis/arthralgia in UC patients and suggest potential benefits in reducing the likelihood of new occurrences or worsening of these events in CD patients even after corticosteroid withdrawal.
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